tbuckley/cabot-search huggingface dataset:
THU0501 Zoledronic Acid Treatment in Bone Marrow Edema Syndrome: Table 1.
Authors: B.J. Flores, J. Sanz Sanz, J. Campos Esteban, M.C. Ramos Giráldez, M. Espinosa Malpartida, M. Bascuas, M. Cuadros, J.L. Andreu, C.M. Isasi Zaragoza, H. Godoy Tundidor, M.M. Jiménez Palop, M.D.C. Barbadillo Mateos, L. Villa Alcázar, J. Mulero Mendoza
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Bone marrow edema (BME) syndrome describes a clinic-radiological entity in which transient subacute or chronic joint pain is associated with characteristic MRI findings (Thiryayi et al.). The etiology remains unknown and can result in significant disability (Guerra et al). Recently, it has been shown that biphosphonates can be used to achieve a reduction in BME (Ringe et al). <h3>Objectives</h3> Our objective was to review the cases of patients diagnosed with BME syndrome in the last 6 years which had also received at least one dose of zoledronic acid <h3>Methods</h3> We accessed the hospital9s Pharmacy database to obtain the zoledronic acid prescriptions from January 2010 to December 2015. Subsequently we selected all the patients with diagnosis of BME syndrome (chronic joint pain AND hypointense on T1-weighted and hyperintense on T2 or STIR sequences). Pain intensity (grade 0: No pain, grade 1: Mild, grade 2: Moderate and grade 3: severe) was measured at baseline, and at 3 and 12 months after treatment with zoledronic acid. MRI changes in bone edema were assessed according to the following scale: Grade 0: No change in edema, Grade 1: Decrease &lt;50% of the initial edema, grade 2: Decrease in &gt;50% of the initial edema, grade 3: Disappearance of bone edema. Functionality was assessed based on whether the patient had returned to his/her daily activities. Finally, complete response was defined as patient fulfilling the following characteristics: Disappearance of pain, or recovery of daily life activities and &gt;50% decrease on bone edema from baseline on MRI. <h3>Results</h3> 17 patients met the inclusion criteria (8 male/9 female), with a mean age of 54 years. Most commonly affected site was the ankle 9 cases (52.9%), followed by the hip: 5 cases (29.4%). 16/17 patients had baseline moderate to severe pain, and 12 months after treatment pain disappeared in 13/17. In those patients with post treatment MRI in the first 3 months (8/17), bone edema had disappeared in 5 patients (62%) and the rest of the MRIs showed a reduction of edema greater than 50%. Finally, 13 of 17 patients (76.4%) had a complete response. <h3>Conclusions</h3> The present study shows that zoledronic acid may be a reasonable therapeutic option in bone marrow edema syndrome, as &gt;75% of the treated patients had a complete response. This is the largest series of patients with bone marrow edema treated with zoledronic acid, but more prospective studies are needed. <h3>Disclosure of Interest</h3> None declared
Treatment with Antibiotics Containing Activity Against Obligate Anaerobes Worsens Gvhd Survival in Mice and Humans after Allogeneic BMT
Authors: Yusuke Shono, Melissa D. Docampo, Odette M. Smith, Jyotsna Gupta, Sophia R. Liberman, Ying Taur, Kenya Honda, Marcel R.M. van den Brink, Robert R. Jenq
Journal: Blood (2014)
Integrative analysis of genetic data sets reveals a shared innate immune component in autism spectrum disorder and its co-morbidities
Authors: Sumaiya Nazeen, Nathan P. Palmer, Bonnie Berger, Isaac S. Kohane
Journal: Genome biology (2016)

Autism spectrum disorder (ASD) is a common neurodevelopmental disorder that tends to co-occur with other diseases, including asthma, inflammatory bowel disease, infections, cerebral palsy, dilated cardiomyopathy, muscular dystrophy, and schizophrenia. However, the molecular basis of this co-occurrence, and whether it is due to a shared component that influences both pathophysiology and environmental triggering of illness, has not been elucidated. To address this, we deploy a three-tiered transcriptomic meta-analysis that functions at the gene, pathway, and disease levels across ASD and its co-morbidities. Our analysis reveals a novel shared innate immune component between ASD and all but three of its co-morbidities that were examined. In particular, we find that the Toll-like receptor signaling and the chemokine signaling pathways, which are key pathways in the innate immune response, have the highest shared statistical significance. Moreover, the disease genes that overlap these two innate immunity pathways can be used to classify the cases of ASD and its co-morbidities vs. controls with at least 70 % accuracy. This finding suggests that a neuropsychiatric condition and the majority of its non-brain-related co-morbidities share a dysregulated signal that serves as not only a common genetic basis for the diseases but also as a link to environmental triggers. It also raises the possibility that treatment and/or prophylaxis used for disorders of innate immunity may be successfully used for ASD patients with immune-related phenotypes.
PTH-079 6-Thioguanine as An Alternative Therapy in Inflammatory Bowel Disease? - Experience in A London District General Hospital
Authors: OS Omer, S Salehi, A Loganayagam
Journal: Gut (2016)

<h3>Introduction</h3> Conventional thiopurines (Azathioprine/6 Mercaptopurine) remain the cornerstone of maintaining remission in steroid-dependent inflammatory bowel disease (IBD). Despite the well-documented efficacy of these drugs, more than 50% of patients discontinue treatment due to adverse events or therapy resistance. Over the past decade, there has been renewed interest in the use of 6 thioguanine (TG), an agent historically used in haematological malignancy. With a shorter metabolic pathway, TG possesses a favourable side effect profile and it’s use as an alternative thiopurine in IBD is growing. We report our experience in tolerability, safety and efficacy of TG use in a London District General Hospital. <h3>Methods</h3> A retrospective review of electronic patient records including clinic letters, blood tests and endoscopic findings were carried out on patients commenced on TG between 2012 and 2015. Data was collected on patient demographics, indication and duration of therapy, response rates and reasons for treatment failure. <h3>Results</h3> A total of 28 patients received TG 20 mg once daily and median treatment duration was 14 months (range 1–40). Therapy was equally distributed amongst males and females (14:14), and mean age was 44 years (range 19–67). 14 (50%) patients had Ulcerative colitis (UC), 13 (46%) Crohn’s disease (CD) and 1 (4%) Indeterminate colitis. 24 patients (86%) received TG due to adverse reactions to conventional thiopurines vs. 3 patients (11%) who were non-responders. Treatment with TG resulted in clinical remission in 86% (19/22) patients at 6 months and 75% (12/16) at 12 months. In total, 6 patients (21%) discontinued TG – 4 failed treatment (2 continued alternative medical therapy and 2 had surgery) and 2 suffered adverse events (headaches and confusion). Tolerability and efficacy rates were similar in both UC and CD groups. All patients underwent blood monitoring and no abnormalities in liver function tests were detected. Of those who underwent MRI liver there was no evidence of nodular regenerative hyperplasia. <h3>Conclusion</h3> TG was well tolerated with comparable remission rates to conventional thiopurine therapy. We advocate the use of TG therapy in selected cases where conventional thiopurine therapy has failed or resulted in adverse reactions. Larger prospective trials are required to further evaluate the efficacy and safety of TG, with a view to potentially incorporate it’s use into clinical guidelines. <h3>Disclosure of Interest</h3> None Declared
FRI0238 Increased Serum Free Light Chains of Immunoglobulins in Systemic Sclerosis Patients: Correlation with Lung Involvement and Inflammatory Milieu
Authors: S.L. Bosello, U. Basile, E. De Lorenzis, G. Canestrari, F. Parisi, M. Rucco, D. Birra, F. Gulli, C. Napodano, K. Pocino, F. Forni, B. Tolusso, G. Ferraccioli
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Humoral immunity and B cells are thought to play an important role in the pathophysiology of the systemic sclerosis (SSc). The production of free light chains (FLC) of immunoglobulins is abnormally high in different pathological autoimmune conditions and reflects B cell activation. Furthermore FLCs demonstrated different biological activities including their capability to modulate the immune system, proteolytic activity, complement cascade activation, as well as FLC binding to antigens and chemotactic factors. <h3>Objectives</h3> To determine the FLC levels in patients with SSc and in healthy controls and to study their possible association with organ involvement and disease characteristics. <h3>Methods</h3> Sixty-five SSc patients (90.0% females; mean age 50.8±17.0 years; 27 (41.5%) with diffuse skin involvement-dcSSc) and 20 age and sex matched healthy controls (HC) were studied. Clinical and immunological inflammatory characteristics were assessed for all the SSc patients. FLC levels were quantified by nephelometry (Freelite TM Human Kappa and Lambda Free Kits, The Binding Site, UK). IL6 and BAFF levels were measured in SSc patients by ELISA. <h3>Results</h3> The mean serum FLC-κ level (SSc: 20.4±7.5 ng/ml <i>vs</i> HC 9.4±4.3 ng/ml, p&lt;0.001) and FLC ratio (SSc: 1.6±0.6 <i>vs</i> HC 0.8±0.2, p&lt;0.001) were significantly higher in patients with SSc compared to healthy controls, while the serum FLC-<sub>λ</sub> levels were comparable (SSc: 13.6±4.8 ng/ml <i>vs</i> HC 11.9±6.2 ng/ml, p=ns). The levels of FLC were comparable in patients with diffuse skin disease and limited skin involvement, while FLC-κ levels were increased in patients with restrctive lung (FVC&lt;79%) disease (SSc: 26.4±7.4 ng/ml) when compared to patients with FVC&gt;79% (HC 19.6±7.3 ng/ml, p=0.009). In SSc patients the levels of serum FLC-κ level directly correlate with the IL-6 levels (R=0.6, p&lt;0.001), while no correlation was found with skin involvement and autoantibodies distribution. <h3>Conclusions</h3> Free light chains of immunoglobulins (sFLC) levels are elevated in systemic sclerosis. High levels of sFLC are associated with the fibrotic lung involvement and with an higher degree of inflammation, supporting the role of B cell activation in the pathophysiology of SSc. <h3>Disclosure of Interest</h3> None declared
Mature Results of a Phase 1-2 Open-Label, Dose-Escalation Study of Intravenous SNS01-T in Patients (pts) with Relapsed or Refractory B-Cell Malignancies
Authors: David S. Siegel, Andrew McDonald, Nicolas Novitzky, William Bensinger, Michael Craig, Frits van Rhee, Martin Gutierrez, Edward N. Libby, John Thompson, Alice S Bexon, Charles Barranco, Catherine A Taylor, Richard Dondero, Leslie J. Browne, Michael R. Kurman, John A. Lust
Journal: Blood (2014)
Incidence of Zika Virus Disease by Age and Sex — Puerto Rico, November 1, 2015–October 20, 2016
Authors: Matthew Lozier, Laura Adams, Mitchelle Flores Febo, Jomil Torres-Aponte, Melissa Bello-Pagan, Kyle R. Ryff, Jorge Munoz-Jordan, Myriam Garcia, Aidsa Rivera, Jennifer S. Read, Stephen H. Waterman, Tyler M. Sharp, Brenda Rivera-Garcia
Journal: MMWR Morbidity and Mortality Weekly Report (2016)

Zika virus is a flavivirus transmitted primarily by Aedes species mosquitoes; symptoms of infection include rash, arthralgia, fever, and conjunctivitis.*,† Zika virus infection during pregnancy can cause microcephaly and other serious brain anomalies (1), and in rare cases, Zika virus infection has been associated with Guillain-Barré syndrome (2) and severe thrombocytopenia (3). This report describes the incidence of reported symptomatic Zika virus disease in the U.S. territory of Puerto Rico by age and sex. During November 1, 2015-October 20, 2016, 62,500 suspected Zika virus disease cases were reported to the Puerto Rico Department of Health (PRDH); 29,345 (47%) were confirmed by reverse transcription-polymerase chain reaction (RT-PCR) testing, or were presumptively diagnosed based on serological testing. The highest incidence among confirmed or presumptive cases occurred among persons aged 20-29 years (1,150 cases per 100,000 residents). Among 28,219 (96.2%) nonpregnant patients with confirmed or presumptive Zika virus disease, incidence was higher among women (936 per 100,000 population) than men (576 per 100,000) for all age groups ≥20 years, and the majority (61%) of reported Zika virus disease cases occurred in females. Among suspected Zika virus disease cases in nonpregnant adults aged ≥40 years, the percentage that tested positive among females (52%) was higher than that among males (47%) (p<0.01). Reasons for the higher incidence of Zika virus disease among women aged ≥20 years are not known; serosurveys of persons living near confirmed Zika virus disease cases might help to elucidate these findings. Residents of and travelers to Puerto Rico should remove or cover standing water, practice mosquito abatement, employ mosquito bite avoidance behaviors, take precautions to reduce the risk for sexual transmission, and seek medical care for any acute illness with rash or fever.
Acute Myeloid Leukemia with Deletion 9q Is Associated with CEBPA Loss-of-Function Mutations.
Authors: Stefan Frohling, Richard F. Schlenk, Jurgen Krauter, Arnold Ganser, Christian Thiede, Gerhard Ehninger, Detlef Haase, Lana Harder, Claudia Scholl, Michael A. Caligiuri, Clara D. Bloomfield, Hartmut Dohner, Konstanze Dohner
Journal: Blood (2004)
Особливості синдрому надлишкового бактеріального росту та порушень мікрофлори кишечника у хворих з портальною гіпертензією
Authors: Yu.M. Stepanov, M.V. Chaliy, I.S. Kononenko
Journal: GASTROENTEROLOGY (2016)

Мета: оцінити клінічні особливості хворих з портальною гіпертензією (ПГ) та синдромом надлишкового бактеріального росту (СНБР). Методи. Під спостереженням перебувало 67 хворих із синдромом портальної гіпертензії, віком від 43 до 81 року, які сформували 2 групи: І група — 60 пацієнтів із печінковою ПГ; ІІ група — 7 хворих із позапечінковою ПГ. Проводили оцінку СНБР за допомогою сучасного газоаналізатора Gastro + Gastolyzer та встановлювали взаємозв’язок отриманих результатів з клінічними даними. Результати. Встановлено, що для пацієнтів із печінковою ПГ СНБР зустрічається частіше (80 %), ніж з позапечінковою ПГ (57 %) (р &lt; 0,05). У хворих із вірусним походженням ПГ та алкогольним етіологічним фактором ПГ СНБР зустрічався з однаковою частотою. Відмічали підвищення трансаміназ у 70,1 % (р &lt; 0,05) пацієнтів з СНБР. Залежності від стадії компенсації захворювання печінки (за Чайлдом — П’ю) та частоти СНБР виявлено не було. Спостерігалась обернена залежність між ступенем печінкової енцефалопатії та частотою СНБР. Висновки. Визначення СНБР водневим дихальним тестом може бути рекомендовано як сучасний, неінвазивний, простий у використанні метод, що дає змогу підвищити оцінку прогнозування та контролю лікування СНБР у хворих із ПГ. Перед призначенням лікування різних форм ПГ слід обов’язково діагностувати СНБР з метою запобігання прогресуванню та розвитку ускладнень.
Safety of Recombinant Activated Factor VII (rFVIIa) in Patients with Congenital Hemophilia with Inhibitors: Overall Dose Exposure and Intervals Following &gt;240 Mcg/Kg Doses Across Trial, Registry and Diary Studies,
Authors: Amy D. Shapiro, Ellis J. Neufeld, Victor S. Blanchette, Hervé Chambost, Peter Salaj, Robert Z. Gut, David L. Cooper
Journal: Blood (2011)
Development and Repurposing of Small-Molecule Kinase Inhibitors to Target Novel Leukemogenic TNK2 Mutations
Authors: Julia Elizabeth Maxson, Abel L Melissa, Jinhua Wang, Xianming Deng, Samuel B Luty, Huahang Sun, Julie Gorenstein, Richard Middleton, Nathanael S. Gray, Brian J. Druker, Jeffrey W. Tyner
Journal: Blood (2014)
PWE-064 The Utility of An Enteric Bacterial PCR Panel In Evaluating Patients with Diarrhoea and Raised Faecal Calprotectin
Authors: S Kumar, J Taylor, T Planche, C Alexakis, A Soubriere, A Poullis, R Pollok
Journal: Gut (2016)

<h3>Introduction</h3> Faecal calprotectin (FCP) assay has an important role in identifying potential cases of inflammatory bowel disease (IBD). However, a significant proportion of patients presenting with diarrhoea and raised FCP do not prove to have IBD following investigation of whom a proportion have an acute self-limiting gut infection. Enteric pathogens are alternative causes of a raised FCP. Alleviating the need for endoscopy in the patients will save money and reduce patient anxiety. However, conventional laboratory methodologies are time consuming and insensitive in detecting gut infection. Commercial nucleic acid amplification test (NAAT) technology now makes it possible to test stool for a panel of gut pathogens quickly and relatively cheaply. In this pilot study, we evaluated this technology in detecting gut infection amongst patients with a diarrhoeal illness and raised FCP, presenting in the community. <h3>Methods</h3> Ninety patients with diarrhoea had stool samples submitted from the community to the laboratory for FCP measurement. Samples were anonymised before testing with NAAT (BD MAX™ Enteric Bacterial Panel). The targets of this assay are <i>Salmonella spp.</i>, Campylobacter spp. Shigella (<i>Shigella spp</i>. and enteroinvasive <i>E. coli</i>) and verotoxigenic <i>E coli</i>. Samples were stratified by FCP level into sub-groups (n = 30): &lt;50, 50–150, &gt;150 µg/g stool and analysed for the presence and type of gut infection found. All samples were also cultured using standard media. <h3>Results</h3> 2/30 samples tested (7%, 95% CI 8–23%) with FCP &gt; 150 µg/g tested positive by NAAT for Campylobacter. No patients with FCP below 150 µg/g had a detectable pathogen. No samples were positive by conventional culture methods. <h3>Conclusion</h3> This pilot study supports a role for the use of multiplex NAAT in detecting enteric pathogens amongst patients with diarrhoea and raised FCP. Prospective studies are required to evaluate this approach further which offers the potential to refine the IBD referral pathways from primary care and reduce the need for endoscopic and radiological tests. <h3>Disclosure of Interest</h3> None Declared
Oxidation of cyanide to cyanate by myeloperoxidase: a new protein carbamylation route involved in cardiovascular diseases
Authors: Cédric Delporte, Karim Zouaoui Boudjeltia, Paul G Furtmüller, Richard Maki, Marc Dieu, Caroline Noyon, Monika M Soudi, Damien Dufour, Vincent Nuyens, Florence Reye, Alexandre Rousseau, Martine Raes, Nicole Moguilevsky, Michel Vanhaeverbeek, Jean Ducobu, Jean Neve, Bernard Robaye, Luc Vanhamme, Wanda Reynolds, Christian Obinger, Pierre Van Antwerpen
Journal: Nature Medicine (2017)
SAT0433 Zoledronic Acid Does Not Slow Spinal Radiographic Progression in Those with Radiographic Osteoarthritis: Table 1
Authors: H.I. Keen, L.V. Host, L.L. Laslett, D.M. Black, G. Jones
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Post-hoc analyses of pivotal studies for osteoporosis therapies such as alendronate<sup>1</sup> and strontium ranelate<sup>2</sup> have demonstrated a reduction in the progression of spinal structural osteoarthritis (OA) measures. There is strong data demonstrating that subchondral bone alterations in osteoarthritis are involved in cartilage degradation. In knee osteoarthritis, zoledronic acid (ZA) improved pain and decreased bone marrow lesion size over 6 months<sup>3</sup>. ZA helps back pain and this benefit is independent of changes in bone mass and fracture<sup>4</sup> suggesting a possible effect on OA. However, there is no data at present on whether ZA influences radiographic OA. We analyzed data from the HORIZON PFT study, in which osteoporotic post-menopausal women were randomised to 36 months of yearly ZA or placebo for fracture reduction. Our aim in this post-hoc analysis was to explore the effect of ZA on spinal osteophytes and disc space narrowing. <h3>Objectives</h3> To assess whether administration of ZA delays the structural progression of spinal osteophytes or disc space narrowing in those with pre-exiting spinal radiographic osteoarthritis. <h3>Methods</h3> A post-hoc blinded analysis of the spinal radiographs HORIZON PFT study was undertaken on a subset of paired spinal radiographs. Post menopausal women that received at least one dose of study medication, and who had both baseline and 36 month spinal radiographs, with a non zero score for spinal osteophytes at baseline were included. Xray scoring of paired images was performed, using the current gold standard method for osteoarthritis<sup>5</sup>; separately for osteophytes and disc narrowing at all evaluable levels from T4–12 and L1–5. <h3>Results</h3> 505 sets of paired radiographs were included in the analysis; 245 in the ZA group and 260 in the placebo group. Overall, rates of change were low but were not different between groups (see table). <h3>Conclusions</h3> ZA was not associated with a slowing of progression of osteophytes or disc space narrowing in the thoraco-lumbar spine in this cohort. <h3>References</h3> Neogi T, et al. ARD. 2008 Oct;67(10):1427–30. Bruyere O, et al. ARD. 2008 Mar;67(3):335–9. Laslett LL, et al. ARD. 2012 Aug;71(8):1322–8. Cauley JA, et al. J Bone Miner Res. 2011 May;26(5):984–92. Lane NE, et al. J Rheum 1993 Nov;20(11):1911–8. <h3>Acknowledgement</h3> This work was supported by a Healy Research Collaboration Award from The Raine Medical Research Foundation, University of Western Australia <h3>Disclosure of Interest</h3> None declared
PWE-139 Audit and Analysis of Turnaround Times in The Endoscopy Suite
Authors: MJ Edmondson, J Thompson, J Morris, A Scarborough, J Hoare
Journal: Gut (2016)

<h3>Introduction</h3> Endoscopic procedures can be subject to large variability due to patient factors. The turnaround time (TAT) between patients offers a more predictable sequence of events, amenable to a sustainable reduction in time through implemented changes. Our primary aim was to reduce TAT at St.Mary's Hospital (SM). Our secondary aim was to identify and compare factors leading to TAT delay at SMH and Charing Cross Hospital (CC), both tertiary centres based in London. <h3>Methods</h3> Clinical observers were used to record TAT and reasons for delay during endoscopy lists at both sites. A TAT was defined as from the point of scope removal from the previous patient to insertion of scope for the next. <h3>Results</h3> 28 TAT were measured at SM during June 2014, with an average TAT of 25 minutes 14 seconds. Nurse-led cannulation was identified as a factor to reduce TAT and partially implemented at SM and CC. From March to May 2015, 44 TAT were recorded at SM (average 20 minutes 49 seconds) and 43 at CC (average 20 minutes 8 seconds), demonstrating a reduction in TAT at SM. Analysis demonstrated significantly more nurse led cannulations in the fastest 20 TAT compared to the slowest 20 TAT (p = 0.01). Endoscopist interruption from non-procedural staff during the TAT also occurred in 25% of TAT across both sites. <h3>Conclusion</h3> Changes in TAT procedure offer sustainable ways to reduce endoscopy list length. Sources of delay are multifactorial, however nurse-led cannulation has been shown to contribute to faster TAT. <h3>Disclosure of Interest</h3> None Declared
Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial
Authors: Serge Gauthier, Howard H Feldman, Lon S Schneider, Gordon K Wilcock, Giovanni B Frisoni, Jiri H Hardlund, Hans J Moebius, Peter Bentham, Karin A Kook, Damon J Wischik, Bjoern O Schelter, Charles S Davis, Roger T Staff, Luc Bracoud, Kohkan Shamsi, John M D Storey, Charles R Harrington, Claude M Wischik
Journal: The Lancet (2016)
P0669 : Consolidation therapy with entecavir can prevent post-treatment HBsAg rebound in HBeAg-positive chronic hepatitis B patients treated with peginterferon alpha
Authors: W.P. Brouwer, M.J. Sonneveld, Q. Xie, N. Zhang, S. Zeuzem, F. Tabak, Q. Zhang, K. Simon, U.S. Akarca, A. Streinu-Cercel, B. Hansen, H.L. Janssen
Journal: Journal of Hepatology (2015)